Product Information
ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML is a generic product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $639.1946 per EA under NDC 00597057550. Its NADAC has been published 42 times since Dec 17, 2025.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597057550
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761058On Market Since
4/30/2024
Price Statistics
The NADAC for ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML has been published 42 times since Dec 17, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $639.1946 per EA |
|---|---|
| All-time high | $639.1946 (Sep 30, 2026) |
| All-time low | $636.0367 (Dec 17, 2025) |
| 52-week high | $639.1946 |
| 52-week low | $636.0367 |
| Median price | $636.5334 |
| Average price | $637.2177 |
| Largest weekly change | +0.1% (May 20, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Adalimumab-adbm market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML?
The current National Average Drug Acquisition Cost (NADAC) for ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $639.1946 per EA (NDC 00597057550), effective Sep 30, 2026.
How has the price of ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML changed over time?
Over the history we have for it, the NADAC for ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML has held within roughly two percent of its current level. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML?
Since Dec 17, 2025, the NADAC for ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML has ranged from a low of $636.0367 (Dec 17, 2025) to a high of $639.1946 (Sep 30, 2026), with a median of $636.5334 per EA.
Are there cheaper alternatives to ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML in a comparable dosage form, but none are currently priced below it.
Who manufactures ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML?
ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML (NDC 00597057550) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a generic product.